ArticleBMC infectious diseases2026
First case report of concurrent infection with Cupriavidus gilardii and Yarrowia lipolytica following esophageal stenosis resection and anastomosis in a newborn.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCupriavidus gilardii and Yarrowia lipolytica are recognized as opportunistic pathogens with a low incidence of human infections. Notably, cases involving concurrent infection by these two pathogens have not been previously documented in the literature. CASE PRESENTATION: We present a case of a 1-month-old male neonate who developed concurrent infection with C. gilardii and Y. lipolytica following surgical resection and anastomosis for congenital esophageal stenosis. The patient developed a postoperative pulmonary infection and subsequent microbiological culture of thoracic drainage fluid confirmed the presence of both C. gilardii and Y. lipolytica. Based on the results of antimicrobial susceptibility testing (AST), the neonate was treated with a combined antimicrobial regimen comprising cefoperazone/sulbactam and fluconazole, and resulting in full clinical and microbiological recovery.
conclusionTo the best of our knowledge, this is the first reported case of a human co-infected with C. gilardii and Y. lipolytica. The clinical course of this case underscores the indispensable role of microbiological laboratory diagnostics in facilitating accurate diagnosis and informing targeted therapeutic strategies. Timely identification and confirmation of pathogen, combined with in vitro AST, can provide active guidance for anti-infective therapy. For immunocompromised patients, high-risk factors predisposing to nosocomial infections such as intubation should be eliminated as soon as possible. Such systematic approaches are essential to avert significant therapeutic delays, prevent clinical deterioration, and avoid futile treatments attributable to unidentified or misidentified pathogens. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.